# Constantine S. Tam

Source: https://onco.cc/people/constantine-tam/  
OnCo record `constantine-tam` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the zanubrutinib SEQUOIA trial and the first ibrutinib-venetoclax study in mantle cell lymphoma.

## Summary

Constantine Tam (Alfred Health, Melbourne) was principal investigator of SEQUOIA, which established zanubrutinib over bendamustine-rituximab in untreated CLL, and led the AIM study, the first trial to combine ibrutinib and venetoclax in mantle cell lymphoma, which produced unexpectedly high complete remission rates. He led the first-in-human zanubrutinib trial and leads lymphoma at Alfred Health.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cll; btk; australia
- Role: Head of Lymphoma Service, Alfred Health; Professor of Haematology, Monash University
- Specialisms: Chronic lymphocytic leukaemia; Mantle cell lymphoma; BTK inhibitors; Venetoclax combinations

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Tam%20CS%5BAuthor%5D%20zanubrutinib%20OR%20ibrutinib%20venetoclax

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- institutions: [Alfred Health / Monash University](https://onco.cc/institutions/alfred-health-monash/)
- trials: [ASPEN (Waldenström macroglobulinaemia)](https://onco.cc/trials/aspen-wm/), [SEQUOIA](https://onco.cc/trials/sequoia/)

---
JSON: https://onco.cc/api/v1/entities/constantine-tam.json